AI and Cancer Research ── 2026-11-16
New papers on cancer and AI, collected from journal feeds, PubMed (searched across all journals) and OpenAlex (a public index used instead of Google Scholar), judged by Jev (an AI that makes language judgements): original research, AI central, which of 13 themes, treatment or trials, and then ranked by importance up to a daily limit. Journals are not filtered by impact factor; each paper shows its journal's IF-equivalent (OpenAlex two-year mean citedness) and the date of that value. Each entry shows the full original abstract.
All cancers: Cancer biology(4)
Hematologic malignancies: AML(1) · CML(0) · ALL(0) · CLL(0) · Lymphoma(0) · Myeloma(0)
Solid tumors: Breast(4) · Lung(2) · Colorectal(0) · Pancreatic(0) · Prostate(0) · Brain(4) · Ovarian(0) · Endometrial(0) · Gastric(0) · Liver(2) · Kidney(1) · Bladder(1)
Rare cancers: ACC(0)
Cancer molecular biology and AI
- Abstract
Explainable deep survival modeling remains challenging due to the performance-explainability trade-off in prognostic models and the gap between feature importance and biological abduction. To address these limitations, we present HGS-BioAbductor, a framework that first constructs a biologically embedded hypergraph neural network for accurate survival prediction. Then, from predictive biomarkers and pathways identified by eXplainable Artificial Intelligence (XAI), it leverages a multi-agent-based tournament process to derive novel molecular mechanisms, and the plausibility and novelty of all hypotheses are quantitatively assessed with automatically queried literature. Across 18 independent clinical proteomics/transcriptomics datasets, HGS achieved the highest C-index in 16/18 benchmarks compared to seven other baselines and outperformed interpretable counterparts by a large margin (+0.1-0.2 C-index). Furthermore, in a case study of hepatocellular carcinoma (HCC), the system demonstrates its ability to propose new hypotheses about previously underexplored proteins in HCC prognosis, e.g., PFKFB2, with strong plausibility in the literature (>0.8), and knockdown experiments in Huh7 and MHCC-LM3 cell lines confirmed that PFKFB2 promotes HCC cell proliferation and colony formation. This work bridges data-driven omics discovery with biological interpretability supported by literature, offering an automated and end-to-end paradigm for clinical omics analysis.
Journal IF-equivalent: 9.8 (OpenAlex 2-year mean citedness, value as of 2026-11-04, retrieved 2026-11-05; not the official Clarivate IF)Reference: Chen Y, Zhang Q, Jiang P, Xie L. HGS-BioAbductor: hypergraph-based explainable survival modelling and LLM-based biological hypothesis abduction. npj Precis Onc. 2026 Nov 14 [Epub ahead of print]. doi:10.1038/s41698-026-01764-9.Checked: Abstract only - Abstract
Accurate differentiation between benign parotid gland tumors (BPGT) and malignant parotid gland tumors (MPGT) is of paramount importance for clinical decision-making and treatment planning. Early and precise diagnosis can significantly influence the choice of therapeutic strategies, patient prognosis, and overall survival rates. Given the clinical significance of distinguishing between BPGT and MPGT, the present study aims to develop a nomogram model that integrates clinical information, ultrasound parameters, and radiomics features extracted from gray-scale ultrasound images to differentiate between BPGT and MPGT. Furthermore, the model’s performance will be evaluated using Shapley Additive Explanations (SHAP) analysis. This retrospective and prospective study examined grayscale ultrasound images from 425 patients diagnosed with parotid gland tumors. 242 patients from Center1 and Center2 constituted the training cohort (including 197 BPGT and 45 MPGT), while 104 patients from Center3 served as the external validation cohort (including 80 BPGT and 24 MPGT). Additionally, 79 patients were prospectively collected from three centers (including 63 BPGT and 16 MPGT) for the prospective validation cohort. Clinic model was developed using clinical data and ultrasound visual information. Radiomics features were extracted from the grayscale ultrasound images to construct radiomics models and corresponding Rad-score. Integrating the Rad score and clinical factors, through multiple logistic regression analysis, to draw a nomogram. These models’ performance was evaluated utilizing receiver operating characteristic (ROC) curve analysis, calibration curves, decision curve analysis (DCA), and the Hosmer-Lemeshow (HL) test. Additionally, SHAP analysis was employed to enhances interpretability in the Rad mode by quantifying and visualizing the impact of each feature on predictions, providing clear insights into model behavior. Four ultrasound visual features were selected using logistic regression (LR) to develop the clinical model, while nineteen features were ultimately chosen from the grayscale ultrasound images through feature screening to construct the radiomics (Rad) model. In the external and prospective validation cohort, compared with Clinic (ACC = 0.769 and 0.785) and Rad (ACC = 0.827 and 0.810), the nomogram showed the best discriminative ability (ACC = 0.817 and 0.848). The nomogram model integrating clinical features and radiomics features constructed in this study has demonstrated higher accuracy and robustness in differentiating BPGT and MPGT. SHAP analysis has enhanced the transparency and interpretability of the model. The model not only support clinical diagnosis and help reduce unnecessary biopsies and surgeries, but also lay the foundation for future multimodal precise diagnosis of parotid gland tumors.
Journal IF-equivalent: 4.8 (OpenAlex 2-year mean citedness, value as of 2026-11-12, retrieved 2026-11-13; not the official Clarivate IF)Reference: Mao Y, Peng XQ, Jiang LP, Diao YH, Wang JL, Chen FQ, et al. Interpretable machine learning model based on gray-scale ultrasound image for noninvasive prediction of BPGT and MPGT. BMC Cancer. 2026 Nov 14 [Epub ahead of print]. doi:10.1186/s12885-026-17264-9.Checked: Abstract only
See all 4 Cancer biology papers →
Hematologic malignancies
Acute myeloid leukemia (AML): treatment, trials and AI
- Abstract
Infections are among the main complications in patients with acute myeloid leukemia (AML) undergoing intensive chemotherapy, increasing morbidity and mortality. However, no established tools exist to detect early signs of infection. Here, we develop and validate a machine learning model to predict the daily risk of febrile neutropenia (FN). We conducted a retrospective observational study using registry data from two university hospital districts in Finland. We included adult patients with newly diagnosed AML undergoing intensive chemotherapy (n = 271, 48-hour FN outcomes=540), excluding acute promyelocytic leukemia. The model used a 48-hour prediction window and 1.2 M clinical data points to generate daily FN risk estimates. We built the model using the Extreme Gradient Boosting algorithm, explained variable importance with Shapley Additive Explanations, and evaluated and validated performance using measures of discrimination, calibration, and clinical utility. We show how seven variables predict daily FN risk: white blood cell count, temperature, time since cycle start, C-reactive protein trend, absolute neutrophil count, treatment phase, and prior antibiotic treatment. We achieve an AUROC of 0.91 (95% CI, 0.89–0.93) and a calibration slope of 0.95 (95% CI, 0.73–1.16) in the development cohort’s test set (n = 55, 48-hour FN outcomes=109) and validate performance in the external cohort (n = 136, 48-hour FN outcomes=124, AUROC 0.79 (95% CI, 0.75–0.82), calibration slope 0.65 (95% CI, 0.51–0.79)). While prospective validation is warranted, this study suggests that routinely collected clinical data may be useful for daily prediction of FN and that further development of such screening tools could potentially support personalized infection prevention. Infections can be a life-threatening complication of chemotherapy in patients with acute myeloid leukemia. Here, we developed a screening tool to help physicians detect these infections early. Using registry data from two Finnish university hospital districts, we trained an AI model to predict early infection onset over the next 48 hours. The model required seven variables, including routine laboratory tests, temperature measurements, time since each chemotherapy cycle started, and information on the treatment phase and antibiotic use. Such a screening tool could potentially support more personalized supportive care. However, the results must be confirmed prospectively before clinical adoption.
Journal IF-equivalent: 8.1 (OpenAlex 2-year mean citedness, value as of 2026-11-13, retrieved 2026-11-15; not the official Clarivate IF)Reference: Mervaala-Muroke A, Toivanen L, Ettala P, Räty R, Keränen M, Brück O. Development and validation of a machine learning model to predict the daily risk of febrile neutropenia in patients with AML undergoing chemotherapy. Commun Med. 2026 Nov 13 [Epub ahead of print]. doi:10.1038/s43856-026-02001-x.Checked: Abstract only
Chronic myeloid leukemia (CML): treatment, trials and AI
No new qualifying paper for this issue.
Acute lymphoblastic leukemia (ALL): treatment, trials and AI
No new qualifying paper for this issue.
Chronic lymphocytic leukemia (CLL): treatment, trials and AI
No new qualifying paper for this issue.
Lymphoma: treatment, trials and AI
No new qualifying paper for this issue.
Multiple myeloma: treatment, trials and AI
No new qualifying paper for this issue.
Solid tumors
Breast cancer: treatment, trials and AI
- Abstract
Unsupervised hierarchical clustering of early-stage breast cancer glycogene expression data using the Growing Hierarchical Self Organising Representation Map (GHSORM) algorithm identified seven subclasses. These glycogene expression clusters (GECs) overlap with known breast cancer biomarkers such as hormone receptor status and immune signatures. Feature discovery via Recursive Feature Elimination with Strikeout (RFES) identified a panel of 60 glycogenes that can predict GECs on an independent testing set with 90.48% accuracy. GEC-based subtyping of patients from the I-SPY2 clinical trial revealed an 86% pathologic complete response (pCR), demonstrating how glycogene expression in combination with custom machine learning algorithms could be an approach to molecular cancer diagnosis capable of informing personalised drug treatment.
Journal IF-equivalent: 4.0 (OpenAlex 2-year mean citedness, value as of 2026-11-15, retrieved 2026-11-16; not the official Clarivate IF)Reference: Venter M, Naidoo KJ. Unsupervised machine learning identifies early stage breast cancer subclasses from aberrant glycogene expression and informs personalised drug treatment. Discov Chem. 2026 Nov 14;3(1):630. doi:10.1007/s44371-026-01070-0.Checked: Abstract only - Abstract
To evaluate whether whole-body CT-derived body composition parameters from routine 18 F-FDG PET/CT provide additional prognostic value beyond tumor metabolic activity in patients with stage I-III HER2-negative breast cancer, irrespective of hormone receptor status. In this retrospective study, 178 patients with stage I-III HER2-negative breast cancer who underwent preoperative 18 F-FDG PET/CT were included. Hormone receptor (HR) status was recorded for all patients but was not an eligibility criterion: patients with HER2-negative disease were eligible irrespective of estrogen receptor (ER) and progesterone receptor (PR) status. Whole-body CT images were analyzed using a deep learning-based TotalSegmentator framework to automatically quantify skeletal muscle (SM), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and intermuscular adipose tissue (IMAT). Associations between imaging-derived parameters and disease-free survival (DFS) were assessed using Cox proportional hazards models and Kaplan-Meier analysis. The incremental prognostic value of body composition parameters beyond SUVmax was evaluated using Harrell’s C-index, likelihood ratio tests, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). During a median follow-up of 41.0 months, 45 patients (25.3%) experienced DFS events. Compared with the non-DFS event group, patients with DFS events showed significantly higher SUVmax, and increased volumes of IMAT, VAT, and SAT, whereas SM volume and attenuation were significantly lower (all P < 0.05). Multivariable Cox regression analysis demonstrated that higher SUVmax, volumes of IMAT and VAT [HR (95% CI): 4.10 (1.97 ~ 8.55), 3.27 (1.17 ~ 9.15), 3.19 (1.45 ~ 7.00), respectively, p all < 0.05] were associated with increased risk of DFS events, whereas higher SM volume was associated with improved DFS [HR (95% CI): 0.53 (0.29 ~ 0.98), P = 0.045]. The association with IMAT volume was not reproduced when the variable was kept continuous (HR per SD 1.32, 95% CI 0.88 ~ 1.98, P = 0.18). Adding body composition parameters (VAT, IMAT, and SM volumes) to SUVmax improved discrimination, increasing the C-index from 0.71 (95% CI, 0.64 ~ 0.78) to 0.82 (95% CI, 0.77 ~ 0.87; P < 0.001), with improvement in risk reclassification (categorical NRI 0.34, 95% CI 0.07 ~ 0.59, P = 0.008; IDI 0.12, 95% CI 0.04 ~ 0.24, P = 0.004). Among all body composition parameters, VAT volume provided the greatest incremental prognostic value. Furthermore, combined stratification based on SUVmax and VAT volume identified four distinct risk groups, with patients exhibiting both high SUVmax and high VAT volume showing the poorest DFS. In HER2-negative breast cancer patients undergoing preoperative 18 F-FDG PET/CT, higher SUVmax and larger VAT volume were associated with poorer DFS, and larger SM volume with better DFS. Adding body composition parameters to SUVmax improved discrimination modestly, with VAT volume showing the strongest contribution. Patients with both high SUVmax and high VAT volume exhibited the poorest DFS. Further prospective validation in larger, multicentre cohorts is warranted.
Journal IF-equivalent: 4.8 (OpenAlex 2-year mean citedness, value as of 2026-11-12, retrieved 2026-11-13; not the official Clarivate IF)Reference: Yuan G, Sun Z, Li Y, Zhou Y. Deep learning-based body composition analysis from 18F-FDG PET/CT provides incremental prognostic value beyond tumor metabolism in HER2-negative breast cancer. BMC Cancer. 2026 Nov 14 [Epub ahead of print]. doi:10.1186/s12885-026-17368-2.Checked: Abstract only
Lung cancer: treatment, trials and AI
- Abstract
Radiomics combined with clinical and dosimetric data may improve outcome prediction after lung stereotactic body radiotherapy (SBRT). This study aimed to develop machine-learning models to predict overall survival (OS) after lung SBRT for primary and metastatic lung tumours using planning-CT-derived features. Clinical and dosimetric data were retrospectively collected from six centres. Radiomic features were extracted using double tumour segmentation and filtered for reproducibility (intraclass correlation ≥ 0.80). From 181 lesions in 158 patients, 180 features (124 radiomic, 45 clinical, 11 dosimetric) were aggregated to the patient level. OS was modelled as a time-to-event outcome using random survival forests, per tumour origin and pooled with tumour origin as a covariate; features were selected by LASSO within cross-validation folds and interpreted with SHAP. The pooled model achieved a concordance index of 0.62 (95% CI 0.54–0.71) with time-dependent AUC of 0.69, 0.62 and 0.52 at 1, 2 and 3 years; a temporal split preserved this (0.61) whereas leave-one-centre-out validation gave a pooled concordance index of 0.57 (95% CI 0.48–0.65). Adding dosimetric and radiomic features to a clinical model increased discrimination (ΔC + 0.12, 95% CI 0.001–0.244). Recurrence- and metastasis-free survival, examined as secondary endpoints, were near chance. These leakage-free, censoring-appropriate models provide an honest, hypothesis-generating benchmark for OS prediction after lung SBRT, most informative at one year, that will require external validation.
Journal IF-equivalent: 5.9 (OpenAlex 2-year mean citedness, value as of 2026-11-04, retrieved 2026-11-05; not the official Clarivate IF)Reference: Invernizzi C, Benveniste PL, El Ayachy R, Leroy T, Blanchard N, Schipman B, et al. Machine learning-based prediction of overall survival after lung SBRT using clinical, dosimetric, and radiomics features: a multicenter study. Sci Rep. 2026 Nov 13 [Epub ahead of print]. doi:10.1038/s41598-026-77575-6.Checked: Abstract only - Abstract
Background: Current guidelines recommend upfront surgery without biopsy for patients with strongly suspected early-stage lung cancer, but this approach may be inappropriate for small cell lung cancer (SCLC). A noninvasive method for preoperatively distinguishing peripheral SCLC (p-SCLC) from peripheral non-small cell lung cancer (p-NSCLC) is crucial.
Methods: This multicenter study included 510 patients with peripheral solid lung nodules ≤ 3 cm, allocated to training set (n = 327), internal test set (n = 141), and prospective external test set (n = 42). After tumor segmentation on pretreatment computed tomography (CT) images, 1,223 radiomic features were extracted. Features were selected using the least absolute shrinkage and selection operator (LASSO) and maximum relevance minimum redundancy (mRMR) algorithms. Based on the filtered features, eight machine learning classifiers were trained on the training set to construct radiomics models. The best-performing radiomics model was subsequently combined with clinical variables to build a hybrid clinical-radiomics model. Performance was assessed using the area under the receiver operating characteristic curve (AUC), calibration analysis, and decision curve analysis (DCA).
Results: The Logistic Regression-based radiomics model showed the highest discrimination, with AUCs of 0.950 (95% confidence interval [CI] 0.916–0.977), 0.938 (0.888–0.978), and 0.919 (0.763–1.000) in the training, internal test, and external test sets, respectively. The hybrid model provided significantly better discrimination, with corresponding AUCs of 0.976 (0.953–0.992), 0.976 (0.949–0.995), and 0.983 (0.944–1.000). Calibration curves and DCA indicated better calibration and greater clinical net benefit for the hybrid model. The hybrid model also maintained good discrimination in subgroup analyses of patients with nodules ≤ 2 cm and patients with negative lymph nodes.
Conclusion: The hybrid clinical-radiomics model noninvasively distinguished p-SCLC from p-NSCLC with high accuracy and may support individualized preoperative evaluation and treatment planning.
Journal IF-equivalent: 4.5 (OpenAlex 2-year mean citedness, value as of 2026-11-13, retrieved 2026-11-15; not the official Clarivate IF)Reference: Liao S, Cao X, Lv D, Qi Q, Zhu K, Yao Y, et al. Machine learning models based on clinical-radiomics features to identify SCLC in ≤ 3 cm peripheral solid lung nodules: a multicenter study. Eur J Med Res. 2026 Nov 12 [Epub ahead of print]. doi:10.1186/s40001-026-05428-z.Checked: Abstract only
Colorectal cancer: screening, treatment, trials and AI
No new qualifying paper for this issue.
Pancreatic cancer: treatment, trials and AI
No new qualifying paper for this issue.
Prostate cancer: treatment, trials and AI
No new qualifying paper for this issue.
Brain tumours: treatment, trials and AI
- Abstract
To assess the feasibility of personalized tumor-masked structural connectomics combined with interpretable machine learning (ML) for differentiating low-grade gliomas (LGG) from high-grade gliomas (HGG), and to identify candidate tract-specific connectomic biomarkers of glioma aggressiveness. Thirty-five patients with histopathologically confirmed gliomas (20 LGG, 15 HGG) underwent preoperative diffusion tensor imaging and T1-weighted MRI. Tumor-masked probabilistic tractography was used to reconstruct individualized structural connectomes based on 50 white matter (WM) tract labels. We evaluated 296 graph-theoretical features using sequential feature selection and Random Forest classification within a strictly isolated nested cross-validation framework. We used SHAP analysis for model interpretation. Sensitivity analyses compared clinical-radiological, connectomic, and combined feature sets. The leak-free pure connectomics model achieved a mean ROC-AUC of 0.814 ± 0.327 (95% CI, 0.500-1.000), with a macro-F1 score of 0.786 ± 0.265. Restricting the analysis to non-zero connectomic features yielded a mean AUC of 0.833 ± 0.167. The clinical-radiological model achieved a mean AUC of 0.817 ± 0.149, while the combined clinical-radiological and connectomic model showed the highest point estimate (AUC, 0.933 ± 0.109; 95% CI, 0.798-1.068). SHAP analysis highlighted the sagittal stratum, medial lemniscus, and superior fronto-occipital fasciculus among the most informative WM pathways. Tumor-masked structural connectomics combined with interpretable ML demonstrated preliminary feasibility for identifying candidate imaging biomarkers associated with glioma aggressiveness in neuroradiological practice. These findings are exploratory and represent internal estimates from a single cohort; external validation in independent, multi-center cohorts is required before any potential clinical application.
Journal IF-equivalent: 2.8 (OpenAlex 2-year mean citedness, value as of 2026-11-12, retrieved 2026-11-13; not the official Clarivate IF)Reference: Franco P, Montalba C, Espinoza I, Cornejo MD, Torres F, Bennett C, et al. Tumor-masked structural connectomics for assessing tract-specific white matter disruption associated with glioma aggressiveness: an interpretable machine learning pilot study. Neuroradiology. 2026 Nov 14 [Epub ahead of print]. doi:10.1007/s00234-026-04232-0. PMID: 43033259.Checked: Abstract only - Abstract
OBJECTIVE: Preoperative knowledge of intracranial meningioma grade could significantly enhance surgical planning, but reliable noninvasive prediction remains an unmet clinical need. The aim of this study was to develop and externally validate a machine learning (ML) model incorporating traditional radiomic features, along with novel fractal and topological features, to predict WHO meningioma grade from preoperative MRI using a large multicenter cohort. METHODS: This retrospective diagnostic study analyzed a cohort of patients in the BraTS Meningioma Challenge. Patient data (n = 909) from 6 academic medical centers were used for model training and internal validation (n = 699) and one-time final external validation (n = 210). Tumors were segmented into three regions and radiomic features extracted across four MRI sequences. Eight different ML algorithms (e.g., based on neural networks, decision trees, clustering, and linear relationships) were tested across a total of 2889 candidate features. The primary outcome was the area under the receiver operating characteristic curve (AUROC) for prediction of binarized WHO grade (1 vs 2 or 3). RESULTS: The final model used a support vector machine algorithm comprising 20 features and achieved an AUROC of 0.824 (95% CI 0.755-0.883) on unseen test data, with favorable calibration. Feature importance analysis revealed that topological complexity added complementary predictive value to conventional radiomics features. The final model is publicly available for anyone to use. CONCLUSIONS: This externally validated ML model accurately predicted meningioma grade using routine preoperative MRI, with the potential to guide surgical decision-making and serve as a basis for future imaging-based brain tumor classifications.
Journal IF-equivalent: 3.9 (OpenAlex 2-year mean citedness, value as of 2026-11-13, retrieved 2026-11-15; not the official Clarivate IF)Reference: Adil SM, Zachem TJ, Warman P, Abdelgadir J, Patel N, Wissel BD, et al. Machine learning prediction of meningioma grade using preoperative MRI: a large multicenter study. J Neurosurg. 2026 Nov 1 [Epub ahead of print]. doi:10.3171/2026.5.jns252856. PMID: 43024876.Checked: Abstract only
Ovarian cancer: treatment, trials and AI
No new qualifying paper for this issue.
Endometrial cancer: treatment, trials and AI
No new qualifying paper for this issue.
Gastric cancer: treatment, trials and AI
No new qualifying paper for this issue.
Liver cancer: treatment, trials and AI
- Abstract
Immunotherapy rechallenge is considered for patients with hepatocellular carcinoma (HCC) after failure or discontinuation of prior PD-1 inhibitor–based therapy. However, reliable pretreatment tools for patient selection remain lacking. In this multicenter retrospective study, 200 patients with HCC who underwent PD-1 inhibitor rechallenge between January 2020 and June 2025 were consecutively enrolled from two centers. Among them, 157 patients from the development center were stratified-randomly assigned in a 7:3 ratio to a training cohort ( n = 109) and testing cohort ( n = 48), while 43 patients from another center served as an independent external validation cohort. The primary endpoint was objective response according to modified Response Evaluation Criteria in Solid Tumors. Three pretreatment models were developed and compared: a clinical model, a 3D deep learning (DL) feature model, and a combined clinical–3D DL model. Model performance was assessed using receiver operating characteristic and precision–recall analyses, calibration, and decision curve analysis. The ability of the models to stratify overall survival and progression-free survival was also explored. The development cohort included 157 patients (training, n = 109; testing, n = 48), of whom 26 (16.56%) achieved an objective response. Among the three models, the combined clinical–3D DL LR model showed favorable overall performance, with AUCs of 0.881, 0.853, and 0.804 and Brier scores of 0.088, 0.095, and 0.130 in the training, testing, and external validation cohorts, respectively. In the external validation cohort, the combined model achieved an accuracy of 0.814, sensitivity of 0.556, specificity of 0.882, and positive predictive value of 0.556. It significantly outperformed the clinical model in both the training ( P = 0.007) and testing ( P = 0.028) cohorts and showed favorable calibration and clinical net benefit. The combined clinical–3D DL model also significantly stratified patients according to both PFS (HR = 0.54, P = 0.008) and OS (HR = 0.55, P = 0.031) and achieved higher discriminative performance than conventional clinical staging and scoring systems. SHAP analysis identified AFP as the most influential predictor, together with multiple arterial- and venous-phase 3D DL features. Pretreatment models integrating clinical variables with CECT-derived 3D DL features showed promising performance for noninvasive prediction of response and survival stratification after PD-1 inhibitor rechallenge in HCC. These findings suggest that the integrated clinical–3D DL model may serve as a potential decision-support tool for patient selection and risk stratification in clinical practice. Further prospective multicenter validation is warranted before clinical implementation.
Journal IF-equivalent: 7.6 (OpenAlex 2-year mean citedness, value as of 2026-11-04, retrieved 2026-11-05; not the official Clarivate IF)Reference: Li Z, Lu Z, Ye C, Huang R, Zhang L. Pretreatment CT-based 3D deep learning feature model for predicting treatment response and stratifying survival after immunotherapy rechallenge in hepatocellular carcinoma. BMC Med Inform Decis Mak. 2026 Nov 14 [Epub ahead of print]. doi:10.1186/s12911-026-03978-0.Checked: Abstract only - Abstract
PURPOSE: To develop and externally validate a peri-ablational contrast-enhanced CT radiomics model for predicting early hepatocellular carcinoma (HCC) progression after microwave ablation (MWA) and to assess its incremental value over clinical predictors. METHODS: This retrospective multicenter study included 376 patients in training (n = 235), internal validation (n = 60), and external validation (n = 81) cohorts. Early progression was defined as local tumor progression or new intrahepatic HCC within 1 year after MWA. Radiomics features were extracted from 5-mm peri-ablational regions on multiphasic CT obtained 1-2 months after MWA. Six machine-learning algorithms and phase combinations were evaluated. The selected radiomics model was combined with independent clinical predictors. Discrimination, calibration, clinical utility, and model interpretability were assessed. RESULTS: The arterial-plus-portal venous phase (AP + PP) multilayer perceptron model achieved AUCs of 0.857, 0.815, and 0.903 in the training, internal validation, and external validation cohorts, respectively, with performance comparable to the three-phase model. Log 10 AFP and tumor size > 2 cm were independent clinical predictors. The combined clinical-radiomics model achieved AUCs of 0.926, 0.884, and 0.963, respectively. In external validation, sensitivity, specificity, and accuracy were 84.2%, 96.8%, and 93.8%, respectively. SHAP analysis identified the radiomics score as the most influential predictor. CONCLUSION: Peri-ablational AP + PP CT radiomics combined with AFP and tumor size demonstrated good discrimination for early HCC progression after MWA and may facilitate individualized risk assessment, pending further validation.
Journal IF-equivalent: 3.1 (OpenAlex 2-year mean citedness, value as of 2026-11-12, retrieved 2026-11-13; not the official Clarivate IF)Reference: Fu Y, Jiao L, Yu P, Meng Z, Qiu S, Wang Y, et al. Peri-ablational contrast-enhanced CT radiomics for predicting early progression of hepatocellular carcinoma after microwave ablation: development and external validation of a clinical–radiomics model. Abdom Radiol (NY). 2026 Nov 12 [Epub ahead of print]. doi:10.1007/s00261-026-05863-w. PMID: 43018705.Checked: Abstract only
Kidney cancer: treatment, trials and AI
- Abstract
BACKGROUND: Cystic renal masses are frequently overtreated. We developed and evaluated the Kidney Imaging-based Triage Engine for Cystic Renal Masses (KITE-CRM), a computed tomography (CT)-based deep-learning pathway using artificial intelligence (AI) to support malignancy risk assessment in cystic renal masses (CRMs). METHODS: We conducted a multicentre development and validation study in China. In phase 1 (January 2020-December 2021), we developed the system in a retrospective training cohort from a tertiary referral center. CRMs were defined as renal lesions with predominantly cystic features. Corticomedullary-phase contrast-enhanced CT was the sole model input. In phase 2 (January 2022-October 2025), we externally validated the model across five independent hospitals. The core task was lesion-level malignancy discrimination; secondary tasks classified malignant lesions as clear-cell renal cell carcinoma (ccRCC) versus other malignant subtypes and stratified ccRCC as high-grade versus low-grade disease. Retrospective cohorts comprised 3150 patients. The core task used 570 training cases (142 malignant), 235 internal-validation cases (137 malignant), and 528 external cases (160 malignant). Three-dimensional processing used one index lesion per patient and a fixed threshold of 0.586442888. In a randomized crossover multi-reader, multi-case study, six radiologists interpreted 117 external-cohort cases with and without AI; outcomes were area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, reading time, and user acceptance. In phase 3 (November 2025-February 2026), 5869 eligible consecutive adults undergoing contrast-enhanced abdominal CT at Changhai Hospital were randomized 1:1 to AI-assisted (n = 2934) or standard reporting (n = 2935). The primary clinical endpoint was the proportion of pathologically benign lesions among treated lesions. The trial was registered with the Chinese Clinical Trial Registry (ChiCTR2500112290); model code is publicly available. FINDINGS: Internal-validation AUROC was 0.996 (95% confidence interval [CI], 0.990-0.999) and Brier score 0.046 (0.036-0.058). External AUROCs were 0.913-0.999, excluding Test 4 (AUROC 1.000; three malignant cases). External sensitivity ranged from 19/24 (79.2%) to 3/3 (100.0%) and specificity from 100/116 (86.2%) to 33/33 and 115/115 (100.0%). AI assistance increased reader-averaged AUROC from 0.825 to 0.973 (difference, 0.149; 95% CI, 0.091-0.206) and reduced mean interpretation time from 9.7 to 5.5 min. Benign pathology occurred in 28/171 (16.4%) treated lesions with AI versus 104/258 (40.3%) with standard care (difference, -23.9 percentage points; 95% CI, -31.7 to -15.4). The treated AI-evaluable CRM subgroup difference was non-significant (5/29 [17.2%] versus 19/56 [33.9%]; p = 0.105). In post hoc intention-to-treat analysis, benign intervention occurred in 28/2934 (0.95%) versus 104/2935 (3.54%) randomized participants (risk difference, -2.59 percentage points; 95% CI, -3.38 to -1.85; p < 0.0001). Median reporting time was 7.6 versus 18.5 min. INTERPRETATION: KITE-CRM improved assisted interpretation and reporting efficiency. Management findings do not establish long-term oncologic safety or CRM-specific clinical superiority. The model complements, rather than replaces, Bosniak assessment, indicated multiphase CT or magnetic resonance imaging (MRI), and clinical judgment. Broader prospective evaluation is needed. FUNDING: National Natural Science Foundation of China and Shanghai municipal research programmes.
Journal IF-equivalent: 15.2 (OpenAlex 2-year mean citedness, value as of 2026-11-13, retrieved 2026-11-15; not the official Clarivate IF)Reference: Chen C, Kang Q, Yang Y, Li X, Li N, Zhang Q, et al. CT-based AI risk support for cystic renal masses: multicenter validation, reader study, and a randomized implementation study. EClinicalMedicine. 2026 Nov;101:104279. doi:10.1016/j.eclinm.2026.104279. PMID: 43022301.Checked: Abstract only
Bladder cancer: treatment, trials and AI
- Abstract
npj Digital Medicine, Published online: 13 November 2026; doi:10.1038/s41746-026-03469-6 Multicenter benchmarking of large language models for bladder cancer management recommendations from mpMRI reports
Journal IF-equivalent: 18.6 (OpenAlex 2-year mean citedness, value as of 2026-11-13, retrieved 2026-11-15; not the official Clarivate IF)Reference: Li Z, Zhang C, Chen X, Kang L, Si Q, Liu Y, et al. Multicenter benchmarking of large language models for bladder cancer management recommendations from mpMRI reports. npj Digit Med. 2026 Nov 13 [Epub ahead of print]. doi:10.1038/s41746-026-03469-6.Checked: Abstract only
Rare cancers
Adenoid cystic carcinoma: treatment, trials and AI
No new qualifying paper for this issue.